Medicines Co. buys Curacyte subsidiary
The Medicines Company is buying Curacyte subsidiary Curacyte Discovery for €14.5 million up front. Curacyte Discovery is developing a serine protease inhibitor in the area of hemostasis and anti-coagulation. Its lead candidate, CU-2010, a treatment for preventing surgical blood loss, is expected to enter Phase I trials by the end of this year. The Medicines Company gains CU-2010 as part of the deal, and Curacyte could receive an additional payment of €10.5 million if the drug proceeds to Phase II clinical development--Curacyte could also earn commercial milestone and royalty payments.
"The transaction will help the parent company, Curacyte, to focus on fully developing its key product, hemoximer, in a pivotal Phase III study in distributive shock," said Dr. Helmut Giersiefen, Curacyte's CEO.
- here's the release
Related Article:
Medicines Company gets not approvable letter
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
